Cargando…

Efficacy of Methotrexate in patients with plaque type psoriasis

Objective: To assess the efficacy of Methotrexate in patients with plaque type psoriasis. Methods: This descriptive study was conducted in the department of Dermatology, Civil Hospital Karachi from September 2009 to March 2010. Seventy three patients between 18 to 50 years of age suffering from plaq...

Descripción completa

Detalles Bibliográficos
Autores principales: Haider, Sabiqa, Wahid, Zarnaz, Najam-us-Saher, Riaz, Farzana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Professional Medical Publicaitons 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4163230/
https://www.ncbi.nlm.nih.gov/pubmed/25225524
http://dx.doi.org/10.12669/pjms.305.4451
_version_ 1782334765221806080
author Haider, Sabiqa
Wahid, Zarnaz
Najam-us-Saher,
Riaz, Farzana
author_facet Haider, Sabiqa
Wahid, Zarnaz
Najam-us-Saher,
Riaz, Farzana
author_sort Haider, Sabiqa
collection PubMed
description Objective: To assess the efficacy of Methotrexate in patients with plaque type psoriasis. Methods: This descriptive study was conducted in the department of Dermatology, Civil Hospital Karachi from September 2009 to March 2010. Seventy three patients between 18 to 50 years of age suffering from plaque type psoriasis with PASI score of >10 were included in the study after taking the informed consent. Oral methotrexate in a dose of 7.5 mg/week was given for 8 weeks. The data collected included demographic profile (age and gender), duration of disease, site of involvement, size of plaque, severity of plaque measured by Psoriasis Area and Severity Index (PASI) score before starting the treatment and at the end of treatment. Efficacy was labeled with a PASI score of ≤5 at the end of 8 weeks. Results: Out of 73 patients there were 45 (61.6%) males and 28 (38.4%) females. The mean ±SD age was 40.0±12.6 years. The mean baseline PASI score showed clear and comparable improvement from a mean ± SD PASI score of 14.8±4.2 to 4.9±4.3.Twenty nine (40%) patients had an almost complete remission during the 8 weeks of treatment. Partial remission was achieved in 44 (60%) patients. The clearance time for psoriasis ranged from 5-7 weeks (mean 6±0.89 weeks). Conclusion: Treatment with methotrexate for chronic plaque psoriasis brings satisfactory disease control and improved quality of life.
format Online
Article
Text
id pubmed-4163230
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Professional Medical Publicaitons
record_format MEDLINE/PubMed
spelling pubmed-41632302014-09-15 Efficacy of Methotrexate in patients with plaque type psoriasis Haider, Sabiqa Wahid, Zarnaz Najam-us-Saher, Riaz, Farzana Pak J Med Sci Original Article Objective: To assess the efficacy of Methotrexate in patients with plaque type psoriasis. Methods: This descriptive study was conducted in the department of Dermatology, Civil Hospital Karachi from September 2009 to March 2010. Seventy three patients between 18 to 50 years of age suffering from plaque type psoriasis with PASI score of >10 were included in the study after taking the informed consent. Oral methotrexate in a dose of 7.5 mg/week was given for 8 weeks. The data collected included demographic profile (age and gender), duration of disease, site of involvement, size of plaque, severity of plaque measured by Psoriasis Area and Severity Index (PASI) score before starting the treatment and at the end of treatment. Efficacy was labeled with a PASI score of ≤5 at the end of 8 weeks. Results: Out of 73 patients there were 45 (61.6%) males and 28 (38.4%) females. The mean ±SD age was 40.0±12.6 years. The mean baseline PASI score showed clear and comparable improvement from a mean ± SD PASI score of 14.8±4.2 to 4.9±4.3.Twenty nine (40%) patients had an almost complete remission during the 8 weeks of treatment. Partial remission was achieved in 44 (60%) patients. The clearance time for psoriasis ranged from 5-7 weeks (mean 6±0.89 weeks). Conclusion: Treatment with methotrexate for chronic plaque psoriasis brings satisfactory disease control and improved quality of life. Professional Medical Publicaitons 2014 /pmc/articles/PMC4163230/ /pubmed/25225524 http://dx.doi.org/10.12669/pjms.305.4451 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Haider, Sabiqa
Wahid, Zarnaz
Najam-us-Saher,
Riaz, Farzana
Efficacy of Methotrexate in patients with plaque type psoriasis
title Efficacy of Methotrexate in patients with plaque type psoriasis
title_full Efficacy of Methotrexate in patients with plaque type psoriasis
title_fullStr Efficacy of Methotrexate in patients with plaque type psoriasis
title_full_unstemmed Efficacy of Methotrexate in patients with plaque type psoriasis
title_short Efficacy of Methotrexate in patients with plaque type psoriasis
title_sort efficacy of methotrexate in patients with plaque type psoriasis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4163230/
https://www.ncbi.nlm.nih.gov/pubmed/25225524
http://dx.doi.org/10.12669/pjms.305.4451
work_keys_str_mv AT haidersabiqa efficacyofmethotrexateinpatientswithplaquetypepsoriasis
AT wahidzarnaz efficacyofmethotrexateinpatientswithplaquetypepsoriasis
AT najamussaher efficacyofmethotrexateinpatientswithplaquetypepsoriasis
AT riazfarzana efficacyofmethotrexateinpatientswithplaquetypepsoriasis